Evidence map›Paper›PMID 33777999›Full record

ArticleFrontiers in molecular biosciences2020

Soluble Epoxide Hydrolase Inhibition Prevents Experimental Type 4 Cardiorenal Syndrome.

Mouad Hamzaoui, Clothilde Roche, David Coquerel, Thomas Duflot, Valery Brunel, Paul Mulder, Vincent Richard, Jérémy Bellien, Dominique Guerrot

Open access · goldAbstract read
In one paragraph

Article in Frontiers in molecular biosciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Mouad HamzaouiNormandie University, UNIROUEN, INSERM U1096, FHU REMOD-VHF, Rouen, France.
Clothilde RocheNormandie University, UNIROUEN, INSERM U1096, FHU REMOD-VHF, Rouen, France.
David CoquerelNormandie University, UNIROUEN, INSERM U1096, FHU REMOD-VHF, Rouen, France.
Thomas DuflotNormandie University, UNIROUEN, INSERM U1096, FHU REMOD-VHF, Rouen, France.
Valery BrunelBiochemistry Department, Rouen University Hospital, Rouen, France.
Paul MulderNormandie University, UNIROUEN, INSERM U1096, FHU REMOD-VHF, Rouen, France.
Vincent RichardNormandie University, UNIROUEN, INSERM U1096, FHU REMOD-VHF, Rouen, France.
Jérémy BellienNormandie University, UNIROUEN, INSERM U1096, FHU REMOD-VHF, Rouen, France.
Dominique GuerrotNormandie University, UNIROUEN, INSERM U1096, FHU REMOD-VHF, Rouen, France.
Université de Rouen Normandie · FRNormandie Université · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

cardiorenal syndromechronic kidney diseaseendothelial (dys)functionepoxyeicosatrienoic acidheart failure

Identifiers

PMID33777999
PMCPMC7991096
OpenAlexW3135284123

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.